Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32688313 | 1.00 | CRBN (0.44) | CRBNDDB1TSHREGFRKDM4E | |
| SCHEMBL1699146 | 0.83 | TSHR (0.47) | CRBNDDB1TSHRKDM4EALDH1A1 | |
| SCHEMBL19807936 | 0.79 | SMN1; SMN2 (0.41) | CRBNDDB1KDM4EALDH1A1POLB | |
| SCHEMBL20595719 | 0.79 | CYP1A2 (0.39) | CRBNDDB1ALDH1A1 | |
| SCHEMBL11545313 | 0.78 | ALDH1A1 (0.41) | CRBNTSHRKDM4EALDH1A1HPGD | |
| SCHEMBL11544043 | 0.77 | DAPK3 (0.37) | CRBNDDB1ALDH1A1IKZF3 | |
| SCHEMBL11550418 | 0.76 | KDM4E (0.40) | CRBNDDB1KDM4EALDH1A1GRM2 | |
| SCHEMBL11544625 | 0.76 | MAPT (0.36) | CRBNDDB1ALDH1A1IKZF3 | |
| SCHEMBL11545281 | 0.75 | KDM4E (0.41) | CRBNDDB1KDM4EALDH1A1HPGD | |
| SCHEMBL11542347 | 0.75 | TP53 (0.40) | CRBNALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339177-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2022-05-24 | — | — | US | disclosed |
| US-20210155635-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2021-05-27 | — | — | US | disclosed |
| EP-2991990-B1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2017-02-01 | — | — | EP | disclosed |
| US-8192918-B2 | Lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8192918-B2 | Lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8192918-B2 | Lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2012-06-05 | — | — | US | disclosed |
| EP-1985445-B1 | A lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2011-07-20 | — | — | EP | disclosed |
| EP-1985445-B1 | A lithographic printing plate precursor | AGFA GRAPHICS NV (BE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100112476-A1 | A LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2010-05-06 | — | — | US | disclosed |
| US-20100112476-A1 | A LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2010-05-06 | — | — | US | disclosed |
| US-20100112476-A1 | A LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2010-05-06 | — | — | US | disclosed |
| WO-2008132091-A1 | A LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA GRAPHICS NV (BE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1985445-A1 | A lithographic printing plate precursor | Agfa Graphics N.V. (BE) | 2008-10-29 | — | — | EP | disclosed |
| EP-1985445-A1 | A lithographic printing plate precursor | Agfa Graphics N.V. (BE) | 2008-10-29 | — | — | EP | disclosed |
| US-4167569-A | ANTICOAGULANTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339177-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same | BAX, LITAF, PNLIP | CRBN 2669/4885DDB1 2110/4885TSHR 3671/4885 |
| US-20210155635-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND METHOD USING THE SAME | BAX, LITAF, PNLIP | CRBN 2669/4885DDB1 2110/4885TSHR 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.